Zobrazeno 1 - 10
of 45
pro vyhledávání: ''
Autor:
Valerio De Stefano, Lucia Pantani, Sonia Morè, Simona Barbato, Luca Dozza, Michele Cea, Alessio Fusco, Maria Teresa Petrucci, Alessandro Gozzetti, Patrizia Tosi, Michele Cavo, Gabriella De Cicco, Elisabetta Antonioli, Paola Tacchetti, Katia Mancuso, Mattia D'Agostino, Serena Rocchi, Elena Rivolti, Elena Zamagni, Ilaria Rizzello
Publikováno v:
Leukemialymphoma. 62(8)
Subcutaneous (SC) bortezomib-based regimens represent the standard induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients. Published data are based principally on intravenous (IV) administr
Autor:
John M. Burke, Michael Boxer, Habte A. Yimer, Gibb study investigators, Sunil Babu, Yeung-Chul Mun, Jeff P. Sharman, Alexey V. Danilov, Jia Li
Publikováno v:
Leukemialymphoma. 62(4)
The single-arm, multicenter, phase 2 GIBB study (NCT02320487) investigated bendamustine plus obinutuzumab (BG) in previously untreated CLL. Patients (N = 102) received six cycles of intravenous obi...
Autor:
Xinxin Cao, Congli Zhang, Hui-Lei Miao, Kaini Shen, Daobin Zhou, Jun Feng, Jian Li, Su Wei, Lu Zhang
Publikováno v:
Leukemialymphoma. 62(4)
Recently, a difference between involved and uninvolved free light chains (dFLC) less than 10 mg/L after treatment (stringent dFLC response) was reported to be associated with superior survival in light-chain (AL) amyloidosis. We conducted a retrospec
Autor:
Kazutoshi Ebisawa, Akira Honda, Arika Shimura, Fumio Nakahara, Mineo Kurokawa, Yosuke Masamoto
Publikováno v:
Leukemialymphoma. 62(3)
Although anti-interleukin-6 therapy with tocilizumab and siltuximab is recommended for multicentric Castleman's disease (MCD), burdens caused by frequent hospital visits and high drug payments is an issue to be considered. Although glucocorticoid mon
Autor:
Aki Sakurai, Tomonori Nakazato
Publikováno v:
Leukemialymphoma. 61(12)
The controlling nutritional status (CONUT) score is an easy-to-use tool for assessing the nutritional status, as it can be estimated based on laboratory information, including the serum albumin lev...
Autor:
Markus Rechsteiner, Rudolf Benz, Markus G. Manz, Corinne C Widmer, Kathrin Zimmermann, Stefan Balabanov
Publikováno v:
Leukemialymphoma. 61(10)
The provisional diagnosis refractory anemia with ring sideroblasts and thrombocytosis was recognized in the WHO 2016 revision of the hematologic neoplasm as a distinct entity and was renamed myelod...
Autor:
Takahiro Karasuno, Hiroyuki Sugahara, Tsuyoshi Kamae, Yuma Tada, Shuji Ueda, Norimitsu Saito, Toru Kida, Satoru Kosugi, Hirohiko Shibayama, Hideki Mitsui, Jun Ishikawa, Manabu Kawakami, Yasuhiko Azenishi, Yozo Uchida, Tetsuhisa Kitamura, Yasuhiro Moriyama, Ruri Kato, Shigeo Fuji, Masashi Nakagawa, Ryoto Sakaniwa, Yoshiki Nakae, Masato Iida, Kenji Nozaki, Hiroaki Masaie
Publikováno v:
Leukemialymphoma. 61(9)
This retrospective, multicenter observational study investigated the prognostic value of pretreatment serum soluble interleukin-2 receptor (sIL-2R) level for outcomes of newly diagnosed follicular lymphoma (FL) grade 1-3a who required treatment at di
Autor:
Ling Zhang, Najla Al Ali, Rami S. Komrokji, Vu H. Duong, Alan F. List, Jeffrey E. Lancet, David A. Sallman, Eric Padron
Publikováno v:
Leukemialymphoma. 61(8)
Thrombocytopenia occurs frequently in patients with myelodysplastic syndromes (MDS), and the survival of patients after failure of hypomethylating agents (HMAs) is poor. We conducted a trial of eltrombopag in patients with MDS, MDS/myeloproliferative
Autor:
C.L. Beach, Aristoteles Giagounidis, Valeria Santini, Antonio Almeida, Barry S. Skikne, Nora Tu, Pierre Fenaux, Jerry Weaver
Publikováno v:
Leukemialymphoma. 61(6)
In the randomized, phase 3, MDS-005 study (NCT01029262), lenalidomide-induced red blood cell transfusion independence (RBC-TI) in 27% of transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS) ineligible for or refr
Autor:
George Nahas, Lazaros J. Lekakis, Mark Goodman, Antonio M. Jimenez, Trent P Wang, Amer Beitinjaneh, Krishna V. Komanduri, Denise Pereira
Publikováno v:
Leukemialymphoma. 61(4)
Anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) have shown dramatic efficacy in treating refractory aggressive B cell Lymphomas leading to FDA approval of axicabtagene ciloleucel and tisagenlecleucel. While long-term remission rate for both is hi